SCM
XBI icon

Stonehill Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stonehill Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-73,700
Closed -$8.25M – 23
2021
Q4 		$8.25M Buy
+73,700
New +$8.89M 1.81% 15

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Stonehill Capital Management's XBI Position: Q1 2022 in Review

Stonehill Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 73,700 shares — an estimated $8.25M sold.

Stonehill Capital Management first reported a position in XBI in Q4 2021 and held it in 1 quarter. The position peaked at $8.25M in Q4 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Stonehill Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Stonehill Capital Management sold 73,700 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $8.25M.
  • Stonehill Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 1 quarter.
  • Stonehill Capital Management's State Street SPDR S&P Biotech ETF position peaked at $8.25M in Q4 2021.
  • 702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Stonehill Capital Management's 13F filing for Q1 2022, filed 16 May 2022.